ViGenCell Inc. was established in February 2013 as the inaugural affiliate of the Catholic University Technology Holdings, leveraging the validated immune cell therapy technologies pioneered by the Catholic University of Korea. Dedicated to the principle of reverence for life, we are committed to developing a sustainable business model, promoting social welfare through advancements in the medical sector, and taking a leading role in fostering collaboration between industry and academia. Additionally, we will enhance our research capabilities and bring cutting-edge technologies to the market to evolve into a successful global pharmaceutical enterprise.